UPLOAD Filing
Protalix BioTherapeutics, Inc.
Date: April 30, 2025 · CIK: 0001006281 · Accession: 0000000000-25-004560
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286802
Letter
Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 28, 2025 File No. 333-286802 Dear Dror Bashan:
April 30, 2025
Dror Bashan President and Chief Executive Officer Protalix BioTherapeutics, Inc. 2 University Plaza, Suite 100 Hackensack, NJ 07601
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Brian D. Hirshberg
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 30, 2025 Dror Bashan President and Chief Executive Officer Protalix BioTherapeutics, Inc. 2 University Plaza, Suite 100 Hackensack, NJ 07601 Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 28, 2025 File No. 333-286802 Dear Dror Bashan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian D. Hirshberg </TEXT> </DOCUMENT>